Slide 1: GLP-131 Phase 1 Study of BMF-650 Week 4 Topline Results
Exhibit 99.1 GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026
Slide 2: Legal Disclaimer & Forward-looking Statements
Legal Disclaimer & Forward-looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve know
Slide 3: Agenda
BMF-650 GLP-131 – A Phase 1 Study of BMF-650 Topline Results Agenda Opening Remarks Ramses Erdtmann Co-Founder, Chief Operating Officer & President, Biomea Fusion Design Hypothesis Thorsten Kirschberg, PhD for BMF-650 Executive VP, Research, Biomea Fusion GLP-131 Topline Juan Pablo Frías, MD Results
Slide 4: Opening Remarks
Ramses Erdtmann Co-Founder, Chief Operating Officer & President, Biomea Fusion Opening Remarks 4
Slide 5: GLP-1 therapies: a large and growing market with a persistence challenge
GLP-1 THERAPIES A large and growing market with a meaningful persistence challenge GLP-1 therapies have transformed obesity treatment, but broad adoption and long-term persistence remain distinct opportunities 100M+ ~1B ~11M Unique U.S. patients using U.S. adults living Adults globally projected GLP
Slide 6: Opportunities for a next-generation GLP-1 receptor agonist
BMF-650 | Phase 1b MAD Opportunities for a next-generation GLP-1 Receptor Agonist Reduce adverse events that can limit treatment More tolerable therapy Reach the targeted dose quicker and with fewer dose Easier and quicker titration increases to achieve simplified administration and early adherence
Slide 7: Design Hypothesis for BMF-650
Thorsten Kirschberg, PhD Executive VP, Research, Biomea Fusion Design Hypothesis for BMF-650 7
Slide 8: A potential differentiated oral next-generation GLP-1 receptor agonist
BMF-650 A potential differentiated oral next-generation GLP-1 receptor agonist designed to separate GI adverse effects from weight loss One-step Designed for Built for Oral titration improved GI persistent administration tolerability use Faster path to Convenience maintenance Intended for without in
Slide 9: BMF-650 designed to reduce on-target agonism for long-term tolerability
BMF-650 | PRECLINICAL BMF-650 was designed to reduce on-target agonism to achieve long-term tolerability BMF-650 is designed as a biased small GLP-1 human β-arrestin molecule GLP-1 receptor agonist, to Compound EC EC selectively engage GLP-1 signaling 50 50 Designed with reduced on-target potency BM
Slide 10: Pharmacokinetics showed enhanced preclinical bioavailability
BMF-650 | PRECLINICAL BMF-650 | PRECLINICAL Pharmacokinetics showed enhanced preclinical bioavailability signals with low variability CYNOMOLGUS MONKEY PO PK DATA SPRAGUE-DAWLEY RAT PO PK DATA BMF-650 showed approx. 2-fold BMF-650 showed approx. 3-fold greater oral bioavailability in greater oral bi
Slide 11: Dose-dependent weight loss in obese monkeys with low emesis
BMF-650 | PRECLINICAL BMF-650 | PRECLINICAL BMF-650 demonstrated robust, dose-dependent weight loss in obese monkeys with low rates of emesis Week Emesis (Vomiting) BMF-650 up to ~15% body weight reduction after 28 days Body Weight Change from Baseline 1 18.2%* 0 2 7.0% -5 3 5.6% -10 4 1.4% Vehicle
Slide 12: Design: next-generation oral small-molecule GLP-1 RA
BMF-650 | Design A next-generation oral small-molecule GLP-1 RA with a differentiated profile designed to separate GI effects from weight loss Broader intestinal Improved oral Gradual, sustained absorption bioavailability systemic exposure Intended to reduce localized Intended to achieve Designed to
Slide 13: GLP-131 Phase 1 Topline Results
Juan Pablo Frías, MD Co-Chair of the Scientific Advisory Board, Biomea Fusion GLP-131 Phase 1 Topline Results Dr. Juan Pablo Frias Chief Medical Officer of Biomea Fusion 13
Slide 14: GLP-131: Phase 1 study design
BMF-650 | Phase 1 BMF-650 | GLP-131 GLP-131: Phase 1 study design Randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and weight reduction with BMF-650 in overweight or obese participants Multiple Ascending Dose (MAD) Phase 1b Single Ascending Dose (SAD) Phase 1a Prim
Slide 15: 1B MAD Baseline Demographics & Characteristics
BMF-650 | Phase 1b MAD BMF-650 | Phase 1B MAD Baseline Demographics & Characteristics Active BMF-650 Cohort 1 Cohort 2 Cohort 3 Cohort 4 MAD Cohorts 1-4 Pooled Doses for Weeks 1–4 10/25/50/100 50/100/200/200 75/150/300/300 75/200/400/400 Total Placebo mg mg mg mg (N=32) (N=8) (N=8) (N=8) (N=8) (N=8)
Slide 16: 1B MAD Clinical efficacy – weight reduction
BMF-650 | Phase 1b MAD BMF-650 | Phase 1B MAD Clinical efficacy – weight reduction Mean percentage change in body weight from baseline at Day 29 Pooled Placebo (n=8) -0.1% Cohort 1 (n=8) -1.5% (10/25/50/100 mg) Cohort 2 (n=8) -2.1% (50/100/200/200 mg) Cohort 3 (n=8) -3.2% (75/150/300/300 mg) Cohort
Slide 17: Analysis of weekly weight reduction
BMF-650 | Phase 1b MAD Analysis of weekly weight reduction Pooled Cohort 1 Cohort 2 Cohort 3 Cohort 4 14 of 16 weekly dosing cohorts showed PLACEBO 10 → 25 → 50 50 → 100 → 75 → 150 → 75 → 200 → incremental weekly absolute weight n=8→ 100 200 → 200 300 → 300 400 → 400 reduction. 10 mg 50 mg 75 mg 75
Slide 18: GLP-131: Phase 1 study design + dose cohort 5
BMF-650 | Phase 1 BMF-650 | GLP-131 GLP-131: Phase 1 study design + dose cohort 5 Randomized, double-blind, placebo-controlled study, evaluating safety, tolerability, and weight reduction with BMF-650 in overweight or obese participants Multiple Ascending Dose (MAD) Phase 1b Single Ascending Dose (S
Slide 19: Baseline demographics & characteristics + dose cohort 5
BMF-650 | Phase 1b MAD BMF-650 | Phase 1B MAD Baseline demographics & characteristics + dose cohort 5 Active BMF-650 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 MAD Pooled Doses for Weeks 1–4 10/25/50/100 50/100/200/200 75/150/300/300 75/200/400/400 200/400/400/400 BMF-650 Total Placebo mg mg mg mg
Slide 20: Analysis of weekly weight reduction with cohort 5 confinement
BMF-650 | Phase 1b MAD Analysis of weekly weight reduction Cohort 5 in-patient confinement Pooled Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 5 used confinement to monitor PLACEBO 10 → 25 → 50 50 → 100 → 75 → 150 → 75 → 200 → 200 → 400 → n=8→ 100 200 → 200 300 → 300 400 → 400 400 → 400 dosin
Slide 21: Primary Endpoint: Overall Treatment-Emergent Adverse Events
BMF-650 | Phase 1b MAD Primary Endpoint: Overall Treatment-Emergent Adverse Events (TEAEs) Active BMF-650 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 MAD Pooled Doses for Weeks 1–4 10/25/50/100 50/100/200/200 75/150/300/300 75/200/400/400 200/400/400/400 BMF-650 Total Placebo mg mg mg mg mg (N=40)
Slide 22: 1B MAD Select Gastrointestinal TEAEs
BMF-650 | Phase 1b MAD BMF-650 | Phase 1B MAD Select Gastrointestinal TEAEs Active BMF-650 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Doses for Weeks 1–4 MAD Pooled 10/25/50/100 50/100/200/200 75/150/300/300 75/200/400/400 200/400/400/400 BMF-650 Total Placebo mg mg mg mg mg Participants, n (%) (N
Slide 23: Competitive Analysis vs late-stage oral GLP-1 Phase 1 disclosures
BMF-650 | Competitive Analysis BMF-650 at highest dose level vs late-stage oral GLP-1 Phase 1 disclosures Select GI tolerability Any TEAE* 70% Lower incidence / More favorable Higher incidence / Less favorable Nausea ◆ BMF-650 12.5% ● Oral GLP-1 comparator 1 ● Oral GLP-1 comparator 2 Vomiting* ● Ora
Slide 24: Class-like changes in liver enzymes, fasting glucose and heart rate
BMF-650 | Phase I 1b MAD Class-like changes in liver enzymes, fasting glucose and heart rate Active BMF-650 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 MAD Pooled Doses for Weeks 1–4 10/25/50/100 50/100/200/200 75/150/300/300 75/200/400/400 200/400/400/400 BMF-650 Total Placebo mg mg mg mg mg (N=40
Slide 25: Target exposure with low peak to trough ratio in human PK
BMF-650 | Phase 1b MAD BMF-650 delivered target exposure with low peak to trough ratio in human PK Selected PK parameters for Cohort 5 Day 28 Cohort 5 Day 28 C (peak plasma 4400 ng/mL max concentration) (+ 26.4%) C (trough plasma 2520 ng/mL min concentration) (+ 39.4%) Peak to trough ratio 1.7 AUC 7
Slide 26: Phase 1 findings support the BMF-650 design hypothesis
BMF-650 | Phase 1b MAD Phase 1 findings provide support for the BMF-650 design hypothesis BMF-650 reached the target dose of 400 mg QD via a single Rapid one-step titration to titration step design post week 1, supporting a potentially simple 400 mg is well tolerated and practical dosing paradigm Su
Slide 27: Next Steps: Advancing BMF-650 development
BMF-650 | Phase 1b MAD Next Steps: Advancing BMF-650 development while optimizing the clinical profile • Highest dose achieved with only a single titration step while maintaining Clinical Findings favorable tolerability • Weight loss as expected in line with other GLP-1 agents • Overall, generally w
Slide 28: Executive Summary
Mick Hitchcock, PhD Interim Chief Executive Officer & Board Member, Biomea Fusion Executive Summary Dr. Juan Pablo Frias Chief Medical Officer of Biomea Fusion 28
Slide 29: Q & A
Q & A Dr. Juan Pablo Frias Chief Medical Officer of Biomea Fusion 29